NLRP3-IN-41_product_DataBase

Bioactivity	NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research[1].
Invitro	NLRP3-IN-41 (5-15 μM, 24 h) 显著抑制 LPS (100 ng/mL) 和 ATP(5 mM) 在 THP-M 中诱导的 IL-1β，并抑制 AIM2 和 NLRC4 炎症小体[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> NLRP3-IN-41 相关抗体:
In Vivo	NLRP3-IN-41 (40, 80 mg/kg, i.g., 10 days) 可减轻 DSS 诱导的 C57BL/6 和 ICR 小鼠的结肠炎症状[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
CAS	1209698-02-1
Formula	C22H22N2O4S2
Molar Mass	442.55
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Yang F, et al. Identification and Validation of PKR as a Direct Target for the Novel Sulfonamide-Substituted Tetrahydroquinoline Nonselective Inhibitor of the NLRP3 Inflammasome. J Med Chem. 2024 Jun 10.

PeptideDB